The frantic race between scientists and pharmaceutical companies to find a vaccine against the "Corona" virus is bearing fruit,
The frantic race between scientists and pharmaceutical companies to find a vaccine against the "Corona" virus is bearing fruit, as the initial results of the "Moderna" company vaccine showed an effectiveness of 94.5% in protection against the "Corona" virus that causes "Covid-19" disease, and that is a week after Similar announcement by "Pfizer" and "Biotank" company, for its vaccine effectiveness of more than 90%, according to "Sky News".
Scientifically speaking, the two vaccines have very similar mechanism of action, while the two differ from the prevailing patterns followed by the usual vaccines.
It was customary for the vaccine to consist mainly of weak or inactivated viruses or parts of the virus that do not cause disease to the body, but rather only inform it of the disease, and stimulate it to produce antibodies that remain inside it for life, and defend it against this virus in the future.
It is this protein, which gives the Corona virus its distinctive coronary shape, that helps the microorganism attach to human cells in the early stages of the disease.
Once this foreign protein is produced in the body, the immune system becomes deluded in the presence of the virus, and it begins producing antibodies, as if the person was already sick .. This method is similar to the way in which the "Pfizer" and "Biontech" vaccines work.
As for the "Moderna" vaccine, it takes a different approach, as it consists of small pieces of "mRNA" DNA, which stimulate the body to produce the protein on the surface of the emerging corona virus.
Among the good news, the Moderna vaccine can be stored in regular refrigerators for six months, and for a month in refrigerators, without losing its effectiveness, unlike the other vaccine, which needs to be stored in extremely cold temperatures of minus 70 degrees.
As for production and manufacturing, the US government has allocated 2.5 billion dollars to Moderna to support research and testing, and to purchase at least 100 million doses of the vaccine, while the company intends to produce 20 million doses this year, all of which will go to the United States.
On the other hand, Pfizer agreed to sell no less than 1.1 billion doses of its vaccine to the United States, Europe and Canada, along with Japan and Britain, and this is about 1.3 billion doses that the company intends to produce by the end of 2021.
Despite this progress in the race to confront the epidemic, the risks are still facing the world, in a research by the Institute of Global Health at Duke University, it was revealed that it is possible that there will not be enough doses to cover the entire world population until 2024.